brontictuzumab brontictuzumab brontictuzumab (inn; development code omp-52m51) is a humanized monoclonal antibody designed for the treatment of cancer. brontictuzumabmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetnotch 1clinical dataother namesomp-52m51atc codenoneidentifierscas number1447814-75-6chemspidernoneuniiuny2tqa40ekeggd11229chemical and physical dataformulac6392h9862n1980o1710s50molar mass143410.36 g·mol−1 this drug was developed by oncomed pharmaceuticals.